ADULT;
ANAMNESIS;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CASE REPORT;
DRUG DOSE REDUCTION;
DRUG MEGADOSE;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
FEMALE;
GLIOBLASTOMA;
GLIOMA;
HUMAN;
MULTIPLE CYCLE TREATMENT;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
RADIATION DOSE;
RECURRENT CANCER;
THROMBOCYTE COUNT;
THROMBOCYTOPENIA;
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression-free survival in recurrent, treatment-refractory glioblastoma (GBM)
TF Cloughesy MD Prados PY Wen, et al. 2008 A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression-free survival in recurrent, treatment-refractory glioblastoma (GBM) J Clin Oncol 26 2010b
Pulsed reduced dose-rate radiotherapy: Case report: A novel re-treatment strategy in the management of recurrent glioblastoma multiforme
DOI 10.1007/s11060-007-9329-z
GM Cannon WA Tomé HI Robins, et al. 2007 Pulsed reduced dose-rate radiotherapy: a novel re-treatment strategy in the management of recurrent glioblastoma multiforme J Neurooncol 83 307 311 10.1007/s11060-007-9329-z 17252184 (Pubitemid 46952243)
Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021
DOI 10.1215/S1522851705000311
HI Robins M Won WF Sieferheld, et al. 2006 A phase II trial of conventional radiation therapy plus high dose tamoxifen for the treatment of supratentorial glioblastoma multiforme: RTOG protocol BR-0021 Neuro Oncol 8 47 52 10.1215/S1522851705000311 1:CAS:528:DC%2BD28Xps1amsA%3D%3D 16443947 (Pubitemid 43154450)
Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer
DOI 10.1038/sj.bjc.6603923, PII 6603923
C Kut F Mac Gabhann AS Popel 2007 Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer Br J Cancer 97 978 985 10.1038/sj.bjc.6603923 1:CAS:528:DC%2BD2sXhtFSnurfE 17912242 (Pubitemid 47519292)
Platelets take up the monoclonal antibody bevacizumab
DOI 10.1158/1078-0432.CCR-07-0847
H Verheul M Lolkema D Qian, et al. 2007 Platelets take up the monoclonal antibody bevacizumab Clin Can Res 13 5341 5347 10.1158/1078-0432.CCR-07-0847 1:CAS:528:DC%2BD2sXhtVCitL%2FJ (Pubitemid 47510358)
Safety of anticoagulation use and bevacizumab in patients with glioma
10.1215/15228517-2008-009 18436627
PL Nghiemphu RM Green WB Pope, et al. 2008 Safety of anticoagulation use and bevacizumab in patients with glioma Neuro Oncol 10 355 360 10.1215/15228517-2008-009 18436627
